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Abstract. Leukemia is a hematologic cancer which develops in blood
tissue and causes rapid generation of not mature and abnormal-shaped
white blood cells. It is one of the most prominent causes of death in both
men and women for which there is currently not an effective treatment.
For this reason, several therapeutical strategies to determine potentially
relevant genetic factors are currently under development, as targeted
therapies promise to be both more effective and less toxic than current
chemotherapy. In this paper, we present a network community cluster-
based analysis for the identification of potential gene drug targets for
Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia.
Keywords: Network analysis, Community clusters, Drug discovery, Ther-
apeutic targets, Leukemia
1 Introduction
Leukemia is known to be a group of cancers that usually begin in the bone
marrow and result in a high number of abnormal white blood cells. Although
its prevalence is low, the chance of surviving is one of the lowest among cancer
diseases. Moreover, the population in developed countries is aging incremen-
tally, and taking into account that older people have a higher risk of developing
Leukemia, a steady increase of cases is to be expected.
Leukemia involves complex genetic factors, and identifying which ones are
relevant to treat the disease can make a difference between life or death. The
treatments for and reactions of each type of Leukemia may vary considerably [1].
The probability of survival can be increased by methods that allow to identify
types of Leukemia accurately, as well as by the use of computational methods for
the discovery of relevant targets in the genome that might be of interest for drug
development [2]. In this paper, we will focus on the task of discovering promising
target genes for the treatment of Acute Lymphoblastic Leukemia (ALL) [3] and
Acute Myeloid Leukemia (AML) [4] types, which represent almost half of the
totality of Leukemia cases.
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The main objective of this paper can be stated as follows: given the gene-
interaction network related to ALL and AML, where some genes are known to
be targets of certain drugs approved by the U.S. Food and Drug Administration
(FDA), as they are highly significant for the disease at hand, and some others
are not (or not known to be), we aim to assess if the topological structure of the
sub-networks related to the genes belonging to the two different classes, namely
target and non-target, have any specificity in terms of statistical properties; we
also want to analyze if, by using network community cluster detection techniques,
it is possible to find potential drug targets.
The rest of the paper is structured as follows: Section 2 introduces the basic
techniques employed in our analysis, as well as the data used in the study.
Then, Section 3 describes and discusses in detail the experimental findings, while
Section 4 concludes the paper and points to issues deserving further research.
2 Materials and methods
2.1 Graph-theoretical centralities
Degree centrality. This paper focuses on graph community cluster analysis
[5]. For this, some graph centrality measures must be defined first. The degree
centrality is defined as the number of edges going into or out of a node.
Betweenness centrality quantifies the number of times a node is in the way







where σst is the total number of shortest paths from node s to node t and σst(v)
is the number of those shortest paths that pass through v.
Closeness centrality of a node is defined as the average length of the shortest
path between the node and all other graph nodes. A variant that accounts for
the possibility of having a not connected graph is known as harmonic centrality,







where d(y, v) is the distance between nodes y and v, imposing that 1d(y,v) = 0 if
there is no path from y to v.
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PageRank centrality. The PageRank centrality [6], which is a variant of the
Eigenvector centrality [7], was originally defined for a scenario where a user surfs
the web by clicking links. The PageRank value of a website is an estimation of the
probability that the user is on a web page at a given moment. Generalizing from
webpages to network nodes, three elements determe the PageRank of a node: the
number of incoming edges, the number of outgoing edges of the linking nodes,
and the PageRank of the linking nodes.
2.2 Random graph null hypothesis: the Erdös-Rényi model
The Erdös-Rényi graph [8] is a random network model where edges are connected
independently between each pair of nodes with a probability p that follows a
Bernoulli distribution, thus they have no community (cluster) structures. This
model has been widely used as a null hypothesis to find patterns in the topology
and community structure of real networks [9]. For this reason, in this work we
use it to study the particular properties of gene-interaction networks.
2.3 Community finding algorithms
Walktrap algorithm. The Walktrap algorithm [10] is a community detection
algorithm that uses a distance metric based on performing random walks and
uses a hierarchical agglomerative clustering method. Formally, if two nodes i and
j belong to the same community, the probability to reach a third node k belong-
ing to the same community by means of a random walk, should differ minimally
for i and j. Then, the distance between two nodes i and j is constructed by
summing these differences over all nodes, with a correction for each node degree.
Infomap algorithm. The Infomap algorithm represents the community-cluster
structure of a graph by means of a two-level nomenclature based on Huffman
coding [11]. It defines the problem of finding the optimal clustering of a graph
as finding a description of minimum information using random walks on the
graph. Moreover, the algorithm objective function is to maximize the so-called
Minimum Description Length [12].
2.4 Data gathering & building the gene-interaction network
The data in our experiments is divided over different sources. First, we searched
for which FDA-approved drugs are currently used to treat ALL and AML types
of Leukemia. This was obtained from the U.S. National Cancer Institute [13].
On the other hand, from the Drug-Gene Interaction Database [14], the genes
that are targeted by a given drug, which total 197, were obtained. Then, in
order to obtain negative samples (non-target genes), we queried human gene
identifiers from HumanMine, a biological database developed by the University
of Cambridge [15, 16]. From a pool of 62,906 genes, 197 were randomly sampled,
constrained to only those genes with at least one known interaction with another
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gene, and that are not known to be a target of any disease. This was done to
obtained a balanced dataset for analysis.
After that, we built the gene-interaction network of both the 197 target and
non-target genes. To do so, for each gene we queried the BioGRID database [17]
for the genes interacting directly with each of the genes in our dataset. Conse-
quently, for each gene we have its direct interacting neighborhood, where some
interacting gene neighbors may be shared among different genes, thus leading
to a connected graph. This resulted in a network comprised of 12,761 nodes and
72,634 edges (see Table 1 for summary information).
Network Nodes Edges
Target Network 11966 50512
Non-target Network 11966 22122
Full 12761 72634
Table 1: Network composition
3 Experimental Results & Discussion
3.1 Description of the network structure
The illustration of the full network is provided in Figure 1, with the node sizes
drawn according to their PageRank [6, 7] value. These values are linearly related
to the dimension of the vertex, where a greater PageRank value corresponds
to a greater dimension of the node. In Figure 1, blue nodes are the non-target
genes and the red ones are the target genes, that are given by approved FDA
drugs for ALL and AML. Also, orange nodes are genes that interact with either
target genes, non-target genes, or both, as is the case when they have common
neighbors. These orange nodes are not known to be targets or non-target genes,
and thus we refer to them as unknown genes from now on.
In order to further characterize our network, we calculate two widely known
graph metrics: the transitivity (also known as clustering coefficient), and the
diameter. We measure these metrics for the full network, the target genes sub-
network and the non-target genes sub-network. The transitivity, T , of a graph,
G, is based on the relative number of triangles in the graph, compared to the
total number of connected triples of nodes. Formally, transitivity T of a graph
G is calculated as
T (G) =
3 × number of triangles in the graph
number of connected triples in the graph
, (3)
where the factor of three in the numerator takes into account the fact that each
triangle contributes to three different connected triples in the graph, one centered
at each node of the triangle.
The diameter of a graph is the length of the longest shortest path between any
two graph vertices, u and v, where d(u, v) is a graph distance, that is, the largest
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Fig. 1: Visualization of the gene-gene interaction network where node sizes are
relative to their PageRank value
number of vertices which must be traversed in order to travel from one vertex to
another, without taking into account loops or backtracking paths. Thus, if the
shortest path between the two farthest nodes in the graph has a length of 3, the
diameter of the graph will have a value of 3.
Network Transitivity Diameter
Target Network 0.1365 10
Non-target Network 0.1436 10
Full 0.1346 10
Table 2: Transitivity and diameter metrics of the full graph and target/non-
target subgraphs
In Table 2, we show the transitivity and diameter metrics of the full network,
as well as for the target and non-target sub-networks. As can be seen, the diame-
ter in the three scenarios is the same, thus the longest shortest path is the same.
Also, the transitivity of the non-target sub-network is higher than the one of the
full and target networks, thus indicating that this sub-network has a higher den-
sity of connections between nodes. Consequently, in the non-target sub-network,
the number of shared interacting genes between the non-target genes is higher
than the corresponding one in the other networks.
In order to study the topology of the graph, we assessed its clustering coeffi-
cient as a measure of characterization of the graph topology, with respect to how
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it would behave in a random scenario, using the the Erdös–Rényi model as our
null hypothesis. The null hypothesis we set is such that the clustering coefficient
of our network is not significantly different to that of a random model, given a
0.95 of confidence (α = 0.05). Consequently, the hypothesis we want to verify
is that the clustering coefficient of our network, and hence, its topology, is due
to its specific nature and not due to a random behaviour. In order to reject or
accept the null hypothesis, we compute the p-value by dividing the number of
times the random model has a higher value than our network, divided by the
total number of times we carry out the experiment. For this study, we build 30
random graph as experimental set and compute the clustering coefficient of each
one.
Moreover, given the size of the graph, and in order to speed up the computa-
tion, we carried out an optimization to calculate the metrics exactly but without
scanning all the graph, bounding the values of the clustering coefficient in the
null hypothesis, CNH , below C
min
NH and above C
max
NH , exploring only a subset of











i=1 Ci + 1 -
M
N .
Then, with the previous formulae, after calculating the clustering coefficient
Ci for only the first M nodes in the network produced by the null hypothesis,
we can compare it with the bounds, and assume that if CminNH ≥ C, then CNH
≥ C, also if CmaxNH < C then CNH < C.
Furthermore, by allowing for a certain degree of error in evaluating C (the
clustering coefficient in our network) and CNH , we can further optimize the
calculation by means of a Monte Carlo procedure. To do so, we order the graph
by doing a uniform permutation of the vertices, and then calculate the clustering
coefficient only for the first M vertices. The value of M we use is based on the
fact that even when M << N , we can get a good estimation of the clustering







Network Erdös–Rényi (random model)
Target Network 0.03
Non-target Network 0
Table 3: Statistical marginal significance (p-value) after the Monte Carlo pro-
cedure on the clustering coefficient. The selected confidence value is 0.95 (α =
0.05).
As shown in Table 3, the p-value with respect to the random network null
hypothesis is lower than the significance level α = 0.05, leading to significant
evidence for the rejection of the null hypothesis. This means that, as our network
clustering coefficient is a particular characteristic of it, our network topology can
be seen as having specific, non-random, characteristics.
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3.2 Community analysis
Since we are dealing with a graph with different node categories, it is worth
investigating if a community detection algorithm is able to detect these underly-
ing clusters. In order to build the communities, we used the previously described
Infomap [11] and Walktrap [10] algorithms, taken from the R package igraph.
Notice that the genes that are not known to be targets or non-targets have been
excluded from the community analysis, as the main idea in this part of the anal-
ysis is to verify if target (or non-target) genes are similar enough, and, due to
the interactions between them and their local topology in the network, they can
be grouped in pure communities or clusters. Here, we define a pure community
or cluster as a group formed of only one type of genes, either targets or non-
targets. Hence, an impure community would be formed of a mixture of targets
and non-targets.
After running the community finding algorithms, we measured the goodness
of the communities found by the two different chosen algorithms. For this, we
rely on different quality measures: Triangle Partition Ratio (TPR), expansion,
conductance and modularity. TPR is the fraction of nodes within a cluster that
belongs to a triad; thus a higher value translates into a clustering with a higher
quality. Expansion is the number of nodes leaving the cluster; thus, a lower value
means a clustering of better quality. Conductance is the fraction of total edge
volume that points outside the cluster; thus, a lower value is better. Modularity
is the difference between the number of edges in the cluster and the expected
number of edges of a random graph with the same degree distribution; thus, a
higher value is better.
Algorithm TPR Expansion Conductance Modularity Communities
Walktrap 0.763 1.216 0.188 0.6 318
Infomap 0.68 6.906 0.394 0.56 370
Table 4: Quality measures of community structure.
The quality metrics for each of the algorithms are summarized in Table 4.
From these results, it is clear that the Walktrap algorithm yields the best values
for TPR, expansion, modularity and conductance. Consequently, by relying ex-
clusively on the values of these heuristic quality metrics to judge the goodness of
the community finding algorithm performance, we can say that the Walktrap al-
gorithm produces the best segmentation of the graph into different communities.
We then proceeded to analyze in more detail such communities.
In Figure 2, we show the percentage of genes per category (target and non-
target) of each community given by the result of the Walktrap community de-
tection algorithm. From this result, we can say that there is a densely connected
cluster of target genes and a densely connected cluster of non-target genes. The
result given by the community finding algorithm is very interesting as, since
it is able to find pure communities of targets, it means that the target genes
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Fig. 2: Communities composition based on the Walktrap algorithm.
have a particularly characteristic topology in the network, thus leading to the
conclusion that it is possible to unveil new targets by means of their structure
on the network (e.g., by taking into account their graph-theoretical centrality).
Then, unknown genes that have characteristics similar to the target genes may
be potential targets.
3.3 Analysis of the network based on centrality measures
After ensuring that the topology of the two types of genes in our network is char-
acteristic, we studied the network using the graph-theoretical centrality measures
described in section 2. Their values for the full network and the target and non-
target sub-networks are summarized in Table 5.
Network Degree Betweenness Closeness
Target 0.0022 0.00021 0.29
Non-target 0.0021 0.00023 0.28
Full 0.0020 0.0002 0.29
Table 5: Average values of the centrality measures in the three networks
Then, given the previous insights, we analyzed the genes with the highest
values for each of the graph-theoretical based centralities, as those are the ones
showing clearer predominant centrality values in the whole network. After that,
we took the genes that were shortlisted in the three sets. Thus we took the genes
that are among the top with respect to their centrality values in all the centrality
measures at the same time.
In Figure 3 the set of genes that have the highest values in all the centralities
is illustrated. As can be seen, this set is comprised of only target and unknown
genes at the same time, pointing out that these unknown genes may be potential
candidates as drug targets for AML and ALL. These genes are HSP90AA1,
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TRIM25, ELAVL1, APP, MCM2, CUL3, HSPA8, XPO1, EGLN3, UBC and
NXF1.
Fig. 3: Set of top shortlisted genes with the highest values in all centrality mea-
sures: degree, closeness and betweenness.
4 Conclusions
This brief paper has reported network analysis and community cluster detec-
tion for the identification of potential drug targets for ALL and AML types of
Leukemia. We have described in detail how we built a gene-interaction network
for the genes targeted by currently FDA approved drugs for ALL and AML, and
for non-target genes obtained from HumanMine, a publicly available biological
database.
The non-randomness (and therefore the topological specificity) of the network
has been asserted. Furthermore, by using the Walktrap and Infomap community
detection algorithms, it has been shown that both target and non-target genes
can be segmented in pure groups. Finally, by analyzing several graph-theoretical
centrality measures, and taking the genes that hold the highest values of these
measures in the network, we were able to identify a set of potential drug target
candidates for ALL and AML.
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This study could be extended to the complete Leukemia spectrum, includ-
ing Chronic Lymphocytic Leukemia, chronic Myelogenous Leukemia, Hairy Cell
Leukemia, Mast Cell Leukemia and Meningeal Leukemia. In addition, it would
be interesting to analyze in more detail the specificities of those genes that were
found to be potential targets, by carrying out a gene set enrichment analysis to
check if, statistically, they have significant pathways affected and their relation
to ALL and AML Leukemias.
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